DK3286206T3 - Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme - Google Patents

Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme Download PDF

Info

Publication number
DK3286206T3
DK3286206T3 DK16783603.0T DK16783603T DK3286206T3 DK 3286206 T3 DK3286206 T3 DK 3286206T3 DK 16783603 T DK16783603 T DK 16783603T DK 3286206 T3 DK3286206 T3 DK 3286206T3
Authority
DK
Denmark
Prior art keywords
ligand
treatment
hybrid actriib
trap proteins
muscle
Prior art date
Application number
DK16783603.0T
Other languages
English (en)
Inventor
Hq Han
Xiaolan Zhou
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Application granted granted Critical
Publication of DK3286206T3 publication Critical patent/DK3286206T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
DK16783603.0T 2015-04-22 2016-04-12 Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme DK3286206T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562150994P 2015-04-22 2015-04-22
US201562262356P 2015-12-02 2015-12-02
PCT/US2016/027046 WO2016171948A1 (en) 2015-04-22 2016-04-12 Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases

Publications (1)

Publication Number Publication Date
DK3286206T3 true DK3286206T3 (da) 2021-05-03

Family

ID=57144520

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16783603.0T DK3286206T3 (da) 2015-04-22 2016-04-12 Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme

Country Status (25)

Country Link
US (4) US10913782B2 (da)
EP (2) EP3286206B1 (da)
JP (2) JP6959487B2 (da)
KR (1) KR20180006386A (da)
CN (1) CN107683287B (da)
AU (2) AU2016251640B2 (da)
BR (1) BR112017022658A2 (da)
CA (1) CA2983440C (da)
CY (1) CY1124124T1 (da)
DK (1) DK3286206T3 (da)
ES (1) ES2856001T3 (da)
HK (1) HK1251588A1 (da)
HR (1) HRP20210725T1 (da)
HU (1) HUE054232T2 (da)
IL (1) IL255070B (da)
LT (1) LT3286206T (da)
MX (1) MX2017013520A (da)
PL (1) PL3286206T3 (da)
PT (1) PT3286206T (da)
RS (1) RS61881B1 (da)
RU (1) RU2733492C2 (da)
SG (2) SG10201913747PA (da)
SI (1) SI3286206T1 (da)
WO (1) WO2016171948A1 (da)
ZA (2) ZA201707821B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
CA2951926C (en) 2014-06-13 2023-01-10 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
EP3280728B1 (en) 2015-04-06 2020-12-16 Acceleron Pharma Inc. Alk7:actriib heteromultimers and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN113683708A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
DK3496739T3 (da) 2016-07-15 2021-05-10 Acceleron Pharma Inc Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
CA3039525A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
US10934532B2 (en) 2016-10-05 2021-03-02 Acceleron Pharma Inc. ALK4.ActRIIB heteromultimers
JOP20190085A1 (ar) * 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018089706A2 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CA3054837A1 (en) * 2017-03-24 2018-09-27 Novartis Ag Methods for preventing and treating heart disease
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP7510875B2 (ja) * 2018-01-12 2024-07-04 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
US20220242956A1 (en) * 2019-05-30 2022-08-04 Acceleron Pharma Inc. Actrii-binding proteins and uses thereof
BR112022015387A2 (pt) * 2020-02-03 2022-10-11 Acceleron Pharma Inc Proteínas actriib variantes e usos das mesmas
WO2021158695A1 (en) * 2020-02-03 2021-08-12 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
WO2021189019A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
WO2022040461A1 (en) * 2020-08-20 2022-02-24 Regeneron Pharmaceuticals, Inc. Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists
US20240181007A1 (en) * 2021-01-08 2024-06-06 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
WO2023141724A1 (en) * 2022-01-28 2023-08-03 35Pharma Inc. Activin receptor type iib variants and uses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
EP1147413B1 (en) 1999-01-21 2006-04-05 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
AU2012204098B2 (en) 2001-04-24 2014-05-15 The Johns Hopkins University Use of follistatin to increase muscle mass
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
CA2526669A1 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
ES2454666T3 (es) * 2003-11-13 2014-04-11 Hanmi Science Co., Ltd. Fragmento Fc de IgG para un vehículo de fármaco y procedimiento para la preparación del mismo
CA2891010C (en) 2004-07-23 2022-09-20 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
AU2015200950B2 (en) 2004-07-23 2017-04-27 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
CA2575563A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
CN104524548A (zh) 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TWI432449B (zh) 2007-02-02 2014-04-01 Acceleron Pharma Inc 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI454479B (zh) * 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
US7960343B2 (en) * 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
NZ602471A (en) 2008-06-26 2014-10-31 Acceleron Pharma Inc Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2009158025A2 (en) 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
HUE045456T2 (hu) 2008-08-14 2019-12-30 Acceleron Pharma Inc GDF csapdák anémia kezelésére történõ alkalmazásra
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP3101029B1 (en) 2008-11-26 2019-04-03 Amgen, Inc Variants of activin iib receptor polypeptides and uses thereof
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
EP3275900A1 (en) 2009-04-27 2018-01-31 Novartis AG Compositions and methods for increasing muscle growth
MX2011013172A (es) 2009-06-08 2012-04-02 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
WO2010151426A1 (en) 2009-06-12 2010-12-29 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
EP3838919A1 (en) 2009-08-13 2021-06-23 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
BR112012005225B8 (pt) 2009-09-09 2023-01-10 Acceleron Pharma Inc Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
ES2869864T3 (es) 2009-11-03 2021-10-26 Acceleron Pharma Inc Procedimientos para el tratamiento de la enfermedad del hígado graso
EP3332796A1 (en) * 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US20110268736A1 (en) 2010-04-30 2011-11-03 Children's Medical Center Corporation Method for treating congenital myopathy
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
ES2869168T3 (es) 2011-10-17 2021-10-25 Acceleron Pharma Inc Composiciones para tratar la mielofibrosis
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
PT2780368T (pt) * 2011-11-14 2018-03-22 Regeneron Pharma Composições e métodos para aumentar a massa muscular e a força muscular antagonizando especificamente gdf8 e/ou activina a
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
PE20142114A1 (es) * 2011-12-19 2015-01-04 Amgen Inc Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EP2912462B1 (en) 2012-10-24 2019-08-07 Celgene Corporation Biomarker for use in treating anemia
AU2013337677B2 (en) 2012-11-02 2018-06-28 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
SG10201706148WA (en) 2013-02-01 2017-08-30 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
US20150148345A1 (en) 2013-11-26 2015-05-28 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
EP3119418B1 (en) 2014-03-21 2022-02-23 Acceleron Pharma Inc. Composition for use in a method of treating or preventing anemia by inhibiting activin b and gdf11
JP6649895B2 (ja) 2014-04-18 2020-02-19 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
KR20170035891A (ko) 2014-06-13 2017-03-31 산타 마리아 바이오테라퓨틱스, 인코포레이티드 제형화된 수용체 폴리펩타이드 및 관련 방법
CA2951926C (en) 2014-06-13 2023-01-10 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
EP3280728B1 (en) 2015-04-06 2020-12-16 Acceleron Pharma Inc. Alk7:actriib heteromultimers and uses thereof
EP3344660A4 (en) 2015-08-31 2019-07-03 National Research Council of Canada TGF-BETA-RECEPTOR-EKTODOMÄNENFUSIONSMOLEKÜLE AND USES THEREOF
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3380121B1 (en) 2015-11-23 2023-12-20 Acceleron Pharma Inc. Actrii antagonist for use in treating eye disorders
CA3014197A1 (en) 2016-02-22 2017-08-31 Ravindra Kumar Actrii antagonists for use in increasing immune activity
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
CA3039525A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Variant actriib proteins and uses thereof

Also Published As

Publication number Publication date
CN107683287A (zh) 2018-02-09
CA2983440C (en) 2024-03-12
JP2018512873A (ja) 2018-05-24
JP2022000027A (ja) 2022-01-04
US11292826B2 (en) 2022-04-05
EP3286206B1 (en) 2021-02-17
US20180148491A1 (en) 2018-05-31
US20220332783A1 (en) 2022-10-20
WO2016171948A1 (en) 2016-10-27
RU2017138537A3 (da) 2019-08-01
PL3286206T3 (pl) 2021-09-13
US11932677B2 (en) 2024-03-19
LT3286206T (lt) 2021-06-10
CN107683287B (zh) 2022-05-06
CY1124124T1 (el) 2022-05-27
US20200362009A1 (en) 2020-11-19
AU2020250216A1 (en) 2020-11-05
AU2020250216B2 (en) 2022-07-14
ZA201707821B (en) 2021-03-31
HRP20210725T1 (hr) 2021-06-25
BR112017022658A2 (pt) 2018-07-17
PT3286206T (pt) 2021-04-01
AU2016251640A1 (en) 2017-11-23
SG10201913747PA (en) 2020-03-30
HK1251588A1 (zh) 2019-02-01
MX2017013520A (es) 2018-05-22
RU2017138537A (ru) 2019-05-22
SG11201708351XA (en) 2017-11-29
EP3286206A1 (en) 2018-02-28
HUE054232T2 (hu) 2021-08-30
CA2983440A1 (en) 2016-10-27
EP3878857A1 (en) 2021-09-15
IL255070B (en) 2022-05-01
US20240262883A1 (en) 2024-08-08
ES2856001T3 (es) 2021-09-27
RU2733492C2 (ru) 2020-10-02
AU2016251640B2 (en) 2020-07-16
US10913782B2 (en) 2021-02-09
IL255070A0 (en) 2017-12-31
JP7320571B2 (ja) 2023-08-03
JP6959487B2 (ja) 2021-11-02
RS61881B1 (sr) 2021-06-30
ZA202007118B (en) 2023-03-29
EP3286206A4 (en) 2018-12-05
SI3286206T1 (sl) 2021-07-30
KR20180006386A (ko) 2018-01-17

Similar Documents

Publication Publication Date Title
DK3286206T3 (da) Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme
DK3326641T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3253865T3 (da) Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3777855T3 (da) Fremgangsmåder til behandling af fibrotiske sygdomme
DK3466394T3 (da) Gangbevægelseshjælpeanordning
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3439635T3 (da) Formuleringer til behandling af fast tumor
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3166628T3 (da) Terapeutisk anvendelse af knoglemorfogenetiske proteiner
DK3548061T3 (da) Behandling af neurologiske sygdomme
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3612208T5 (da) Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
DK3157522T3 (da) Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
DK3374495T3 (da) Forbedrede fremgangsmåder til vævsfremstilling
DK3578562T3 (da) L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3585808T3 (da) Modificerede serpiner til behandlingen af bradykinin formidlet sygdom
DK3506901T3 (da) Anvendelse af kynurensyre til behandling af muskelatrofi
DK3169405T3 (da) Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme